DDrare: Database of Drug Development for Rare Diseases

75. クッシング病
［臨床試験数：191，薬物数：172（DrugBank：48），標的遺伝子数：61，標的パスウェイ数：121］

Searched query = "Cushing disease", "Cushing"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE; (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE; 17beta-hydroxy-11beta-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one; 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one; 18F-DOPA; 1H-Pyrazol; 2S,4R-(-)-ketoconazole; 2S,4R-(-)-ketoconazole, levoketoconazole; ATR-101; AZD4017; AZD4017 and prednisolone; Abiraterone; Abiraterone Acetate; Acetate; Acthrel; Bexarotene; CABERGOLINE; CABERGOLINE TEVA; CI-984; CIALIS - 20 MG 2 COMPRESSE RIVESTITE CON FILM IN BLISTER USO ORALE; COR-003; CORT125134; Cabergoline; Calcium; Calcium carbonate; Carbonate; Corticotropin; Corticotropin-releasing hormone; Cushing's syndrome confirmation; Cyclo ((diaminoethyl-carbamate)HyPro-Phg-(D) Trp-Ly di-aspartate; Cyclo ((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Ly di-aspartate; Cyclo((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe) di-aspartate; Cyclo(diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe); DDAVP; DOSTINEX; Device: IPC; Device: continuous glucose monitoring; Dexamethasone; Diagnostic Test: 24-hour Urine test; Diagnostic Test: Blood test; Diagnostic Test: CT scan; Diagnostic Test: Dexamethasone test; Diagnostic Test: MRI; Diagnostic Test: Saliva swab; Dostinex; Dotatate; Eplerenone; Gefitinib; Genotropin 12mg; Genotropin 5.3mg; Genotropin Miniqu; Genotropin Miniquick 0.2mg; Genotropin Miniquick 0.4mg; Genotropin Miniquick 0.6mg; Genotropin Miniquick 0.8mg; Genotropin Miniquick 1.0mg; Genotropin Miniquick 1.2mg; Glucocorticoids; Glucophage (metformin); Glucose; HRA052015; HRA052015 (mifepristone); Hydrocortisone; Hypro; Insulin; KETOCONAZOLE; Ketoconazole; L0006CP03A; LA; LCI699; LCI699, 1 mg; LCI699, 10 mg; LCI699, 20 mg; LCI699, 5 mg; LMWH/Rivaroxaban; Lapatinib; Levoketoconazole; Levoketozonazole; Liqourice; Liraglutide; METYRAPONE; MIFEPRISTONE; Matyrapone; Metformin; Methionine; Metopirone; Metopirone 250 mg capsules; Metopirone 250 mg capsules/Cormeto; Metyrapone; Mifedren; Mifepristone; NIZORAL; Nevanimibe; Nevanimibe hydrochloride; Nizoral; OROCAL; OSILODROSTAT; OSTEOPOR; Octreotide; Osilodrostat; Osilodrostat 10mg; Osilodrostat 1mg; Osilodrostat 20mg; Osilodrostat 5mg; Ossein hydroxyapatite; Other: Control; Other: Hydrocortisone; Other: Obese; Other: [11C]-Methionine PET/MRI; Ovine Corticotropin-Releasing Hormone (oCRH); PASIREOTIDE; PASIREOTIDE DIASPARTATE; PASIREOTIDE PAMOATE; Pasireotida; Pasireotida 300; Pasireotida 600; Pasireotida 900; Pasireotide; Pasireotide 0.3mg; Pasireotide 0.6 MG/ML; Pasireotide 0.6mg; Pasireotide 0.9 mg; Pasireotide 20mg; Pasireotide 40mg; Pasireotide 60mg; Pasireotide LAR; Pasireotide pamoate; Pasireotide s.c.; Pasireotide sub-cutaneous; Pasireotide with or without cabergoline; Pasireotode; Pentetreotide; Phe; Prednisolone; Procedure: Hypercortisolism; Procedure: Lateral transperitoneal LA; Procedure: Posterior RA; R-roscovitine; RVG 08938; RVG 15375; RVG 18236; Radiation: DOTATATE PET-CT; Radiation: F-DOPA PET CT; Relacorilant; Rivaroxaban; Rosiglitazone; Rosiglitazone maleate; SIGNIFOR; SOM230; SOM230 300µg; SOM230 600µg; SOM230 900µg; SOM230 LAR; SOM230 LAR 10 mg; SOM230 LAR 30 mg; SOM230 LAR, 20 mg; SOM230 s.c.; SOM230, 300micrograms; SOM230, 600 micrograms; SOM230, 900 micrograms; SOM230B; SOMATROPIN; Seliciclib; Signifor; Sitagliptin; Somatropin; Tadalafil; Tretinoin; Trp; Tyr; Valsartan; Vorinostat

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02574793 (ClinicalTrials.gov)	December 1, 2014	9/10/2015	Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects	Characteristics of Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects	Pituitary Adenoma	Device: continuous glucose monitoring	Huashan Hospital	NULL	Completed	N/A	N/A	All	60		China
2	EUCTR2009-010918-30-IE (EUCTR)	11/08/2009	11/03/2009	Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism.	Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism.	20 patients with hypopituitarism including growth hormone deficiency will be evaluated both on growth hormone replacement and when they have been off it for a 2 month period. They will have been prescribed growth hormone replacement in the form of Genotropin/Genotropin Miniquick/Norditropin prior to inclusion in this study as part of their routine clinical care. MedDRA version: 9.1;Level: LLT;Classification code 10021067;Term: Hypopituitarism MedDRA version: 9.1;Classification code 10033662;Term: Panhypopituitarism MedDRA version: 9.1;Classification code 10056438;Term: Growth hormone deficiency MedDRA version: 9.1;Classification code 10011318;Term: Craniopharyngioma MedDRA version: 9.1;Classification code 10036832;Term: Prolactinoma MedDRA version: 9.1;Classification code 10011651;Term: Cushing's disease MedDRA version: 9.1;Classification code 10035104;Term: Pituitary tumour MedDRA version: 9.1;Classification code 10061538;Term: Pituitary tumour benign	Trade Name: Genotropin 5.3mg INN or Proposed INN: SOMATROPIN Trade Name: Genotropin 12mg INN or Proposed INN: SOMATROPIN Trade Name: Genotropin Miniquick 0.2mg INN or Proposed INN: SOMATROPIN Trade Name: Genotropin Miniquick 0.4mg INN or Proposed INN: SOMATROPIN Trade Name: Genotropin Miniquick 0.6mg INN or Proposed INN: SOMATROPIN Trade Name: Genotropin Miniquick 0.8mg INN or Proposed INN: SOMATROPIN Trade Name: Genotropin Miniquick 1.0mg INN or Proposed INN: SOMATROPIN Trade Name: Genotropin Miniquick 1.2mg INN or Proposed INN: SOMATROPIN Trade Name: Genotropin Miniqu	Amar Agha, Beaumont Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20		Ireland

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02574793
(ClinicalTrials.gov)

December 1, 2014

9/10/2015

Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects

Characteristics of Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects

Pituitary Adenoma

Device: continuous glucose monitoring

Huashan Hospital

NULL

Completed

N/A

All

China

EUCTR2009-010918-30-IE
(EUCTR)

11/08/2009

11/03/2009

Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism.

20 patients with hypopituitarism including growth hormone deficiency will be evaluated both on growth hormone replacement and when they have been off it for a 2 month period. They will have been prescribed growth hormone replacement in the form of Genotropin/Genotropin Miniquick/Norditropin prior to inclusion in this study as part of their routine clinical care.
MedDRA version: 9.1;Level: LLT;Classification code 10021067;Term: Hypopituitarism
MedDRA version: 9.1;Classification code 10033662;Term: Panhypopituitarism
MedDRA version: 9.1;Classification code 10056438;Term: Growth hormone deficiency
MedDRA version: 9.1;Classification code 10011318;Term: Craniopharyngioma
MedDRA version: 9.1;Classification code 10036832;Term: Prolactinoma
MedDRA version: 9.1;Classification code 10011651;Term: Cushing's disease
MedDRA version: 9.1;Classification code 10035104;Term: Pituitary tumour
MedDRA version: 9.1;Classification code 10061538;Term: Pituitary tumour benign

Trade Name: Genotropin 5.3mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin 12mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 0.2mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 0.4mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 0.6mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 0.8mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 1.0mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniquick 1.2mg
INN or Proposed INN: SOMATROPIN
Trade Name: Genotropin Miniqu

Amar Agha, Beaumont Hospital

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Ireland